User:Swansongcih

"The proprietary technologies complement and online pregnancy test questionnaire enhance the existing portfolio of drug delivery capabilities available from SurModics and Brookwood. Forward-looking statements involve inherent risks and uncertainties, and important factors could cause actual results to differ materially from those anticipated, including the following. SRDX), a leading provider of surface cocaine drug testing another promising development program in diabetes to our broad portfolio of customer programs.

Today, PR Pharmaceuticals is already a customer of Brookwood for biodegradable polymer, which home testing kits it uses in support of current development programs. Statements that are not historical or current facts, including statements about beliefs and expectations, such as the statement that the acquisition is expected to be accretive, excluding one-time charges, or the statement that the new technologies poise SurModics to drive customer programs and long-term revenue, are forward-looking statements. A broader toolkit for protein delivery and the ability to use smaller gauge needles for microparticle injections make an even more compelling offering for both current and future SurModics customers. Howe, chairman and CEO preventing substance abuse of PR Pharmaceuticals. Anticipated Acquisition Benefits -- Broadens SurModics' proprietary technology portfolio in systemic drug delivery, including protein delivery -- Enables delivery of injectable microparticles through smaller testing kits gauge needles -- Expands SurModics' customer base to incorporate several new pharmaceutical and biotech companies -- Immediately adds new sources of revenue and is expected to be accretive to SurModics fiscal 2009 earnings "The proprietary technologies and existing business we are acquiring from PR Pharmaceuticals are a perfect fit for SurModics," said Dorian Patrice, president and CEO of SurModics.

"We are drug abuse detection pleased to consummate this important transaction, and look forward to a long and successful association with SurModics," said Padraic R. For more information, please visit. The acquisition is expected to be accretive to home test hiv SurModics' fiscal 2009 earnings, excluding any one-time charges related to the acquisition. The market for injectable basal insulin is estimated at approximately $4 billion worldwide. Also, the use of smaller needles is an advantage in many other applications requiring subcutaneous or intra-muscular injections, and in particular where patient self-administration is desired. "First, we along with Brookwood are committed to providing a smooth transition for current PR Pharmaceuticals customers to Brookwood. Further, with the addition of these new technologies, SurModics test kits is poised to drive customer programs and long-term revenue even more effectively." The proprietary technologies acquired from PR Pharmaceuticals have broad applicability home test for diabetes and address key needs, enabling the delivery of injectable drugs, including proteins, using biodegradable microparticles through smaller diameter needles compared to competing technologies. (1) our reliance on third parties (including our customers ovulation test and licensees) and their failure to successfully develop, obtain regulatory approval for, market and sell products incorporating our technologies may adversely affect our business operations, our ability to realize the full potential of our pipeline, and the company's ability to achieve our fiscal 2008 corporate goals; (2) costs or difficulties diabetes test relating to the integration of the businesses of Brookwood Pharmaceuticals, BioFX Laboratories, and the drug delivery assets and collaborative projects acquired from PR Pharmaceuticals, Inc., with SurModics' business may be greater than expected and may adversely affect the company's results of operations and financial drug test kits condition; (3) developments in the regulatory environment, as well as market and economic conditions, may adversely affect our business operations and profitability; and (4) other factors identified under "Risk Factors" in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended, and updated in our subsequent reports filed with the SEC.

"In online pregnancy test site wwwamericanpregnancyorg particular, the ability to use smaller gauge needles for injections is of significant interest to customers in ophthalmology and several other clinical areas. Current efforts include a sustained drug delivery system in human trials for treatment of retinal disease and the drug delivery polymer matrix on the first-to-market drug-eluting coronary stent. PR Pharmaceuticals (PRP) is a biopharmaceutical company developing bioactive compounds in injectable sustained-release urine drug testing kit technologies.

The PR Pharmaceuticals technologies will complement those of SurModics and its Brookwood Pharmaceuticals business unit and broaden the overall technology portfolio for the benefit of current and future customer projects. Drug delivery technologies (coatings, microparticles, and implants); surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and specialized surfaces for cell culture and microarrays. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to develop and commercialize innovative products that result in improved patient outcomes. We look forward to aiding PR Pharmaceuticals in radon test kits the manufacturing scale-up and in the production of both clinical trial materials and final product for InsuLAR." "The combined drug delivery expertise of SurModics, Brookwood, and PR Pharmaceuticals is exceptional," said Omero P.

The content of SurModics' website is not part of this release or part of any filings the company makes with the SEC. Proteins and other large molecule therapeutics are of strategic interest to many biotechnology and pharmaceutical companies, but pose significant challenges for drug delivery. These reports are available in the Investors section of our website at and at the SEC website at. Second, the transaction will significantly advance the development of InsuLAR.

"We are very pleased to be working together and look forward to our continued relationship." About SurModics, Inc. Tipton, Ph.D., vice president of SurModics and president of Brookwood. Finally, SurModics will be the paid development partner for PR Pharmaceuticals' proprietary product called InsuLAR(TM), a once-a-week sustained release formulation of basal insulin for the diabetes marketplace. Adamis, M.D., president and CEO of Jerini Ophthalmic, Inc. Collaboration with the technical team and the cGMP manufacturing infrastructure at Brookwood will help ensure successful development and commercialization of InsuLAR as well as provide for a smooth transition for current PR Pharmaceuticals customers. For more diabetes test information about the company, visit.

While our immediate focus is commercialization of InsuLAR, we anticipate working with SurModics on other collaborative programs in the future." "Brookwood Pharmaceuticals gains several attractive assets by vir of this transaction, which strengthens our portfolio of drug delivery technologies and will greatly benefit our customer development programs," said Arthur J. PRP is applying compelling and patented technology to focus its development efforts in rapidly moving InsuLAR, its long-acting basal insulin, into clinical trials. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them in light of new information or future events.. The company has developed significant intellectual property in manufacturing and formulation technologies for the encapsulation saliva drug testing kits of large molecules such as proteins and peptides as well as classic small molecules into biodegradable microparticles. SurModics is headquartered in Eden Prairie, Minnesota and its Brookwood Pharmaceuticals subsidiary is located in Birmingham, Alabama. In addition to the intellectual property being acquired, SurModics will be assuming responsibility for several customer-paid development projects currently in progress with pharmaceutical and biotechnology companies, including Jerini Ophthalmic. Is a leading provider of surface modification and drug delivery technologies to the healthcare industry.

SurModics paid $3 million in cash at closing and may pay up to an additional $6 million in cash upon the successful achievement of certain milestones. The multiple customer development programs we are assuming in this transaction are a strong fit with the diversified portfolio of customer projects at Brookwood and will further leverage the investment we are

 Home Testing Kits SuperStore - USA Shipping